{"hands_on_practices": [{"introduction": "A cornerstone of modern theranostics is quantitative imaging, where metrics from scans like PET are used to guide therapy. However, the physical limitations of scanners mean that what we measure is not always the full truth. This exercise delves into the partial volume effect (PVE), a phenomenon that can cause the measured uptake in small tumors to appear lower than it actually is. By working through this problem, you will learn how to use a recovery coefficient ($RC$) to correct for this effect, providing a more accurate assessment of tumor biology that can be critical for determining a patient's eligibility for targeted therapy [@problem_id:5070201].", "problem": "In translational medicine, theranostic workflows routinely integrate diagnostic imaging with therapy selection, often relying on quantitative positron emission tomography (PET) metrics such as the Standardized Uptake Value (SUV). Consider a spherical lesion of diameter $10\\ \\mathrm{mm}$ imaged with PET. The measured standardized uptake value is $SUV_{\\mathrm{meas}} = 3.0$. For this lesion size, a phantom-calibrated recovery coefficient $RC = 0.5$ has been determined using systems-level characterization of the scanner’s point spread function (PSF). Starting from the foundational definition of SUV, the concept of image formation as a convolution with a finite PSF, and the definition of recovery coefficient as the ratio of measured to true activity concentration for a uniform object, derive the relationship between the partial volume effect and the measured $SUV$, then compute the partial volume–corrected $SUV$. Finally, discuss how this correction could alter whether the lesion meets a hypothetical theranostic therapy eligibility threshold $SUV_{\\mathrm{th}} = 5.0$. Express the corrected SUV as a unitless value and round your answer to three significant figures.", "solution": "The problem statement has been validated and is deemed sound. It is scientifically grounded in the principles of nuclear medicine and medical physics, specifically concerning quantitative positron emission tomography (PET). The problem is well-posed, objective, and provides all necessary information to derive a unique solution. The given values are physically plausible. We may therefore proceed with the solution.\n\nThe problem requires the derivation of the partial volume-corrected Standardized Uptake Value ($SUV_{\\mathrm{corr}}$) and its calculation, followed by a discussion of its theranostic implications. We begin by establishing the foundational principles.\n\n1.  **Standardized Uptake Value ($SUV$)**: The $SUV$ is a semi-quantitative metric that normalizes the measured radiotracer concentration in a region of interest ($C_{\\mathrm{ROI}}$) by the injected dose ($A_{\\mathrm{inj}}$) and patient weight ($W$). Its definition is:\n    $$\n    SUV = \\frac{C_{\\mathrm{ROI}}}{A_{\\mathrm{inj}} / W}\n    $$\n    This formula indicates that the $SUV$ is directly proportional to the measured activity concentration, $C_{\\mathrm{ROI}}$.\n\n2.  **Image Formation and Partial Volume Effect (PVE)**: A PET scanner has a finite spatial resolution, characterized by a Point Spread Function ($PSF$). The measured image, $I_{\\mathrm{meas}}(\\vec{r})$, is the convolution of the true activity distribution, $A_{\\mathrm{true}}(\\vec{r})$, with the system's $PSF(\\vec{r})$:\n    $$\n    I_{\\mathrm{meas}}(\\vec{r}) = (A_{\\mathrm{true}} * PSF)(\\vec{r})\n    $$\n    For objects with dimensions comparable to or smaller than the scanner's spatial resolution (typically $4$–$8\\ \\mathrm{mm}$ Full Width at Half Maximum), this convolution leads to a blurring known as the Partial Volume Effect (PVE). For a hot lesion in a colder background, PVE causes an underestimation of the apparent activity concentration within the lesion's volume. The measured activity concentration ($C_{\\mathrm{meas}}$) is therefore lower than the true activity concentration ($C_{\\mathrm{true}}$). The lesion in question, with a diameter of $10\\ \\mathrm{mm}$, is in the size range where PVE is significant.\n\n3.  **Recovery Coefficient ($RC$)**: The $RC$ is an empirical factor used to quantify and correct for PVE for an object of a specific size and shape. It is defined as the ratio of the measured activity concentration to the true activity concentration:\n    $$\n    RC = \\frac{C_{\\mathrm{meas}}}{C_{\\mathrm{true}}}\n    $$\n    Since PVE causes signal underestimation for hot spots, the $RC$ is typically less than $1$. An $RC$ of $1$ would imply perfect recovery of the true signal.\n\n**Derivation of the Correction Formula**\n\nWe can establish a relationship between the measured $SUV$ ($SUV_{\\mathrm{meas}}$), the true $SUV$ ($SUV_{\\mathrm{true}}$), and the $RC$. From the definition of $SUV$, we have:\n$$\nSUV_{\\mathrm{meas}} = \\frac{C_{\\mathrm{meas}}}{A_{\\mathrm{inj}} / W} \\quad \\implies \\quad C_{\\mathrm{meas}} = SUV_{\\mathrm{meas}} \\cdot \\frac{A_{\\mathrm{inj}}}{W}\n$$\nand\n$$\nSUV_{\\mathrm{true}} = \\frac{C_{\\mathrm{true}}}{A_{\\mathrm{inj}} / W} \\quad \\implies \\quad C_{\\mathrm{true}} = SUV_{\\mathrm{true}} \\cdot \\frac{A_{\\mathrm{inj}}}{W}\n$$\nSubstituting these expressions for $C_{\\mathrm{meas}}$ and $C_{\\mathrm{true}}$ into the definition of the Recovery Coefficient:\n$$\nRC = \\frac{C_{\\mathrm{meas}}}{C_{\\mathrm{true}}} = \\frac{SUV_{\\mathrm{meas}} \\cdot (A_{\\mathrm{inj}} / W)}{SUV_{\\mathrm{true}} \\cdot (A_{\\mathrm{inj}} / W)}\n$$\nThe normalization term $(A_{\\mathrm{inj}} / W)$ cancels, yielding the direct relationship between the quantities:\n$$\nRC = \\frac{SUV_{\\mathrm{meas}}}{SUV_{\\mathrm{true}}}\n$$\nThe partial volume–corrected $SUV$, which we denote as $SUV_{\\mathrm{corr}}$, is conceptually the same as the true $SUV$, $SUV_{\\mathrm{true}}$. Rearranging the equation to solve for $SUV_{\\mathrm{corr}}$ gives the correction formula:\n$$\nSUV_{\\mathrm{corr}} = \\frac{SUV_{\\mathrm{meas}}}{RC}\n$$\nThis relationship shows that to correct for signal loss due to PVE, the measured $SUV$ must be divided by the appropriate recovery coefficient.\n\n**Calculation of the Corrected SUV**\n\nThe problem provides the following values:\n-   Measured $SUV$: $SUV_{\\mathrm{meas}} = 3.0$\n-   Recovery Coefficient for the $10\\ \\mathrm{mm}$ lesion: $RC = 0.5$\n\nUsing the derived formula, we compute the corrected $SUV$:\n$$\nSUV_{\\mathrm{corr}} = \\frac{3.0}{0.5} = 6.0\n$$\nThe problem requests the answer to be expressed to three significant figures. Therefore, the result is $6.00$.\n\n**Discussion of Theranostic Implications**\n\nThe final part of the task is to discuss how this correction could alter a clinical decision based on a hypothetical theranostic eligibility threshold, $SUV_{\\mathrm{th}} = 5.0$.\n\n-   **Without Correction**: The measured value is $SUV_{\\mathrm{meas}} = 3.0$. Comparing this to the threshold, we find $3.0 < 5.0$. Based on this uncorrected measurement, the lesion's avidity for the radiotracer does not meet the criterion for therapy ($SUV_{\\mathrm{meas}} < SUV_{\\mathrm{th}}$). The patient would be deemed ineligible for the targeted therapy.\n\n-   **With Correction**: The partial volume–corrected value is $SUV_{\\mathrm{corr}} = 6.00$. Comparing this to the threshold, we find $6.00 > 5.0$. Based on this corrected, more accurate estimate of the true biological uptake, the lesion does meet the criterion for therapy ($SUV_{\\mathrm{corr}} > SUV_{\\mathrm{th}}$). The patient would be deemed a suitable candidate for the treatment.\n\nThis analysis demonstrates the critical importance of quantitative accuracy in theranostic applications. The partial volume effect, if uncorrected, can lead to a significant underestimation of tumor radiotracer uptake, particularly for smaller lesions. This can result in a false negative interpretation, incorrectly classifying a patient as a non-responder and denying them a potentially beneficial targeted therapy. Applying a partial volume correction, as done here, can therefore dramatically alter and improve the accuracy of clinical decision-making in personalized medicine.", "answer": "$$\\boxed{6.00}$$", "id": "5070201"}, {"introduction": "Once we have an accurate measure of radiotracer activity in an organ over time, the next step is to calculate the absorbed dose—the amount of energy deposited per unit mass, which is directly related to the biological effect. This practice introduces the standard Medical Internal Radiation Dose (MIRD) formalism, where the absorbed dose $D$ is calculated from the time-integrated activity $\\tilde{A}$ and a pre-calculated $S$-value. This exercise not only provides practice with this fundamental calculation but also introduces the vital concept of uncertainty propagation, teaching you how to quantify the confidence in your dose estimate based on the uncertainties in your measurements [@problem_id:4936147].", "problem": "A patient undergoing Prostate-Specific Membrane Antigen (PSMA) targeted radioligand therapy with Lutetium-177 ($^{177}\\mathrm{Lu}$) receives serial quantitative imaging to estimate organ kinetics for internal dosimetry under the Medical Internal Radiation Dose (MIRD) formalism. The mean absorbed dose is defined fundamentally as energy imparted per unit mass to a defined target region, and, in internal emitters, the mean dose to an organ is computed by combining the time-integrated activity in source regions with radionuclide- and geometry-specific dose factors. The time-integrated activity is the integral of activity over time, and the dose factor (known as the $S$-value) is the mean absorbed dose to a target per unit time-integrated activity in a source; the $S$-value encapsulates radiation emission, energy absorption, organ mass, and geometry for the emission and target configuration.\n\nFor the kidneys considered as separate target organs (left and right), assume the following measured quantities from quantitative imaging and standard phantom computations:\n- Left kidney time-integrated activity: $\\tilde{A}_{\\mathrm{L}} = 120~\\mathrm{MBq\\cdot h}$ with standard uncertainty $u(\\tilde{A}_{\\mathrm{L}}) = 12~\\mathrm{MBq\\cdot h}$.\n- Right kidney time-integrated activity: $\\tilde{A}_{\\mathrm{R}} = 95~\\mathrm{MBq\\cdot h}$ with standard uncertainty $u(\\tilde{A}_{\\mathrm{R}}) = 9.5~\\mathrm{MBq\\cdot h}$.\n- Left kidney organ-level $S$-value (kidney self-dose for $^{177}\\mathrm{Lu}$): $S_{\\mathrm{L}} = 0.0062~\\mathrm{Gy}/(\\mathrm{MBq\\cdot h})$ with standard uncertainty $u(S_{\\mathrm{L}}) = 0.00031~\\mathrm{Gy}/(\\mathrm{MBq\\cdot h})$.\n- Right kidney organ-level $S$-value (kidney self-dose for $^{177}\\mathrm{Lu}$): $S_{\\mathrm{R}} = 0.0074~\\mathrm{Gy}/(\\mathrm{MBq\\cdot h})$ with standard uncertainty $u(S_{\\mathrm{R}}) = 0.00037~\\mathrm{Gy}/(\\mathrm{MBq\\cdot h})$.\n\nAssume the following to ensure scientific realism and a well-posed computation:\n- The absorbed dose to each kidney is dominated by the kidney self-dose for $^{177}\\mathrm{Lu}$ emissions, and cross-fire contributions from other organs are negligible for this calculation.\n- The input quantities $\\tilde{A}_{\\mathrm{L}}$, $\\tilde{A}_{\\mathrm{R}}$, $S_{\\mathrm{L}}$, and $S_{\\mathrm{R}}$ are uncorrelated.\n- The reported standard uncertainties are standard deviations representing Type A and Type B components combined, suitable for first-order uncertainty propagation.\n\nUsing the foundational definitions above without invoking shortcut formulas, compute the mean absorbed dose to each kidney and propagate the uncertainty from the given inputs under first-order (linear) uncertainty propagation. Express the final numerical values for the left kidney mean absorbed dose, its standard uncertainty, the right kidney mean absorbed dose, and its standard uncertainty in Gray, and round each of the four numbers to three significant figures. Provide your final answer as four numbers in a single row in the order: left kidney mean dose, left kidney standard uncertainty, right kidney mean dose, right kidney standard uncertainty.", "solution": "The problem is scientifically grounded, well-posed, and objective. All necessary data and assumptions are provided to compute a unique and meaningful solution. The context is an application of the standard Medical Internal Radiation Dose (MIRD) formalism, and the provided numerical values are realistic for radioligand therapy. Therefore, a solution can be derived.\n\nThe fundamental relationship for the mean absorbed dose $D$ in a target organ from a source organ, as per the MIRD formalism, is given by the product of the time-integrated activity $\\tilde{A}$ in the source and the $S$-value for the specific target-source pair. The problem specifies that only the self-dose is to be considered, meaning the source and target organ are the same, and contributions from other organs are negligible.\n\nThe absorbed dose to the left kidney, $D_{\\mathrm{L}}$, is therefore the product of the time-integrated activity in the left kidney, $\\tilde{A}_{\\mathrm{L}}$, and the self-dose $S$-value for the left kidney, $S_{\\mathrm{L}}$.\n$$D_{\\mathrm{L}} = \\tilde{A}_{\\mathrm{L}} \\cdot S_{\\mathrm{L}}$$\nSubstituting the given values:\n$$D_{\\mathrm{L}} = (120~\\mathrm{MBq\\cdot h}) \\cdot (0.0062~\\mathrm{Gy}/(\\mathrm{MBq\\cdot h})) = 0.744~\\mathrm{Gy}$$\n\nSimilarly, the absorbed dose to the right kidney, $D_{\\mathrm{R}}$, is the product of the time-integrated activity in the right kidney, $\\tilde{A}_{\\mathrm{R}}$, and the self-dose $S$-value for the right kidney, $S_{\\mathrm{R}}$.\n$$D_{\\mathrm{R}} = \\tilde{A}_{\\mathrm{R}} \\cdot S_{\\mathrm{R}}$$\nSubstituting the given values:\n$$D_{\\mathrm{R}} = (95~\\mathrm{MBq\\cdot h}) \\cdot (0.0074~\\mathrm{Gy}/(\\mathrm{MBq\\cdot h})) = 0.703~\\mathrm{Gy}$$\n\nNext, we must propagate the uncertainties. For a general function $Y = f(X_1, X_2, \\dots, X_N)$, the combined standard uncertainty $u(Y)$ is found using a first-order Taylor series expansion. Assuming the input variables $X_i$ are uncorrelated, the square of the combined uncertainty is given by:\n$$u(Y)^2 = \\sum_{i=1}^{N} \\left( \\frac{\\partial f}{\\partial X_i} \\right)^2 u(X_i)^2$$\nwhere $u(X_i)$ is the standard uncertainty of the input variable $X_i$.\n\nFor a function that is a product of two uncorrelated variables, such as $D = \\tilde{A} \\cdot S$, the partial derivatives are $\\frac{\\partial D}{\\partial \\tilde{A}} = S$ and $\\frac{\\partial D}{\\partial S} = \\tilde{A}$. Applying the formula gives:\n$$u(D)^2 = S^2 \\cdot u(\\tilde{A})^2 + \\tilde{A}^2 \\cdot u(S)^2$$\nIt is often more convenient to work with relative uncertainties. Dividing both sides by $D^2 = (\\tilde{A} \\cdot S)^2$:\n$$\\left( \\frac{u(D)}{D} \\right)^2 = \\frac{S^2 \\cdot u(\\tilde{A})^2}{(\\tilde{A} \\cdot S)^2} + \\frac{\\tilde{A}^2 \\cdot u(S)^2}{(\\tilde{A} \\cdot S)^2} = \\left( \\frac{u(\\tilde{A})}{\\tilde{A}} \\right)^2 + \\left( \\frac{u(S)}{S} \\right)^2$$\n\nFor the left kidney, we first compute the relative uncertainties of the inputs:\nRelative uncertainty in $\\tilde{A}_{\\mathrm{L}}$: $\\frac{u(\\tilde{A}_{\\mathrm{L}})}{\\tilde{A}_{\\mathrm{L}}} = \\frac{12~\\mathrm{MBq\\cdot h}}{120~\\mathrm{MBq\\cdot h}} = 0.1$\nRelative uncertainty in $S_{\\mathrm{L}}$: $\\frac{u(S_{\\mathrm{L}})}{S_{\\mathrm{L}}} = \\frac{0.00031~\\mathrm{Gy}/(\\mathrm{MBq\\cdot h})}{0.0062~\\mathrm{Gy}/(\\mathrm{MBq\\cdot h})} = 0.05$\n\nThe squared relative uncertainty in $D_{\\mathrm{L}}$ is the sum of the squares of the input relative uncertainties:\n$$\\left( \\frac{u(D_{\\mathrm{L}})}{D_{\\mathrm{L}}} \\right)^2 = (0.1)^2 + (0.05)^2 = 0.01 + 0.0025 = 0.0125$$\nThe standard uncertainty $u(D_{\\mathrm{L}})$ is then:\n$$u(D_{\\mathrm{L}}) = D_{\\mathrm{L}} \\cdot \\sqrt{0.0125} = 0.744~\\mathrm{Gy} \\cdot \\sqrt{0.0125} \\approx 0.083168~\\mathrm{Gy}$$\n\nFor the right kidney, we follow the same procedure:\nRelative uncertainty in $\\tilde{A}_{\\mathrm{R}}$: $\\frac{u(\\tilde{A}_{\\mathrm{R}})}{\\tilde{A}_{\\mathrm{R}}} = \\frac{9.5~\\mathrm{MBq\\cdot h}}{95~\\mathrm{MBq\\cdot h}} = 0.1$\nRelative uncertainty in $S_{\\mathrm{R}}$: $\\frac{u(S_{\\mathrm{R}})}{S_{\\mathrm{R}}} = \\frac{0.00037~\\mathrm{Gy}/(\\mathrm{MBq\\cdot h})}{0.0074~\\mathrm{Gy}/(\\mathrm{MBq\\cdot h})} = 0.05$\n\nThe squared relative uncertainty in $D_{\\mathrm{R}}$ is:\n$$\\left( \\frac{u(D_{\\mathrm{R}})}{D_{\\mathrm{R}}} \\right)^2 = (0.1)^2 + (0.05)^2 = 0.01 + 0.0025 = 0.0125$$\nThe standard uncertainty $u(D_{\\mathrm{R}})$ is:\n$$u(D_{\\mathrm{R}}) = D_{\\mathrm{R}} \\cdot \\sqrt{0.0125} = 0.703~\\mathrm{Gy} \\cdot \\sqrt{0.0125} \\approx 0.078598~\\mathrm{Gy}$$\n\nFinally, the problem requires rounding the four numerical results to three significant figures.\n- Left kidney mean absorbed dose: $D_{\\mathrm{L}} = 0.744~\\mathrm{Gy}$\n- Left kidney standard uncertainty: $u(D_{\\mathrm{L}}) \\approx 0.0832~\\mathrm{Gy}$\n- Right kidney mean absorbed dose: $D_{\\mathrm{R}} = 0.703~\\mathrm{Gy}$\n- Right kidney standard uncertainty: $u(D_{\\mathrm{R}}) \\approx 0.0786~\\mathrm{Gy}$\n\nThe final answer consists of these four values in the specified order.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.744 & 0.0832 & 0.703 & 0.0786\n\\end{pmatrix}\n}\n$$", "id": "4936147"}, {"introduction": "The ultimate goal of theranostics is to deliver truly personalized medicine, and this practice puts you in the clinical driver's seat. Here, you will synthesize the principles of quantitative imaging and dosimetry to solve a core treatment planning problem: how much radiopharmaceutical should be administered? You will use pre-therapy imaging data to calculate the optimal activity that delivers a lethal dose to the tumor while ensuring the dose to healthy, critical organs remains below their safety limits. This exercise embodies the central challenge and promise of theranostics—maximizing therapeutic efficacy while minimizing toxicity for each individual patient [@problem_id:4936218].", "problem": "A theranostic Lutetium-177 labeled peptide treatment is planned for a patient with a single dominant tumor. Pre-therapy Single Photon Emission Computed Tomography (SPECT) imaging with a tracer microdose has been used to quantify the time-integrated activity (cumulated activity) $\\tilde{A}$ per unit administered activity for the tumor and two Organ At Risk (OAR): kidneys and red marrow. Assume linear kinetics between the microdose and the therapeutic dose, negligible cross-fire between regions, and that the absorbed dose is dominated by self-dose in each region.\n\nThe measured $\\tilde{A}$ per unit administered activity are:\n- Tumor: $\\tilde{A}_{\\mathrm{T}}/A_{\\mathrm{admin}} = 0.40\\ \\mathrm{MBq \\cdot h / MBq}$,\n- Kidneys: $\\tilde{A}_{\\mathrm{K}}/A_{\\mathrm{admin}} = 0.18\\ \\mathrm{MBq \\cdot h / MBq}$,\n- Red marrow: $\\tilde{A}_{\\mathrm{M}}/A_{\\mathrm{admin}} = 0.040\\ \\mathrm{MBq \\cdot h / MBq}$.\n\nFor this patient’s geometry, the Medical Internal Radiation Dose $S$-values (mean absorbed dose per unit cumulated activity) for Lutetium-177 are provided as:\n- $S(\\mathrm{T} \\leftarrow \\mathrm{T}) = 7.5 \\times 10^{-3}\\ \\mathrm{Gy / (MBq \\cdot h)}$,\n- $S(\\mathrm{K} \\leftarrow \\mathrm{K}) = 9.0 \\times 10^{-3}\\ \\mathrm{Gy / (MBq \\cdot h)}$,\n- $S(\\mathrm{M} \\leftarrow \\mathrm{M}) = 6.0 \\times 10^{-3}\\ \\mathrm{Gy / (MBq \\cdot h)}$.\n\nThe clinical goal is a target mean tumor absorbed dose of $D_{\\mathrm{target}} = 24$ $\\mathrm{Gy}$. The OAR absorbed dose limits for this single cycle are $D_{\\mathrm{K,max}} = 20$ $\\mathrm{Gy}$ for kidneys and $D_{\\mathrm{M,max}} = 2.0$ $\\mathrm{Gy}$ for red marrow.\n\nUsing foundational dosimetry principles, compute the administered activity $A_{\\mathrm{admin}}$ that achieves the target tumor dose while respecting the OAR limits. Express your final answer in $\\mathrm{GBq}$ and round your answer to three significant figures.", "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\nThe givens are extracted verbatim:\n- Time-integrated activity per unit administered activity for the tumor: $\\tilde{A}_{\\mathrm{T}}/A_{\\mathrm{admin}} = 0.40 \\, \\mathrm{MBq \\cdot h / MBq}$.\n- Time-integrated activity per unit administered activity for the kidneys: $\\tilde{A}_{\\mathrm{K}}/A_{\\mathrm{admin}} = 0.18 \\, \\mathrm{MBq \\cdot h / MBq}$.\n- Time-integrated activity per unit administered activity for the red marrow: $\\tilde{A}_{\\mathrm{M}}/A_{\\mathrm{admin}} = 0.040 \\, \\mathrm{MBq \\cdot h / MBq}$.\n- $S$-value for tumor self-dose: $S(\\mathrm{T} \\leftarrow \\mathrm{T}) = 7.5 \\times 10^{-3} \\, \\mathrm{Gy / (MBq \\cdot h)}$.\n- $S$-value for kidneys self-dose: $S(\\mathrm{K} \\leftarrow \\mathrm{K}) = 9.0 \\times 10^{-3} \\, \\mathrm{Gy / (MBq \\cdot h)}$.\n- $S$-value for red marrow self-dose: $S(\\mathrm{M} \\leftarrow \\mathrm{M}) = 6.0 \\times 10^{-3} \\, \\mathrm{Gy / (MBq \\cdot h)}$.\n- Target mean tumor absorbed dose: $D_{\\mathrm{target}} = 24 \\, \\mathrm{Gy}$.\n- Kidneys absorbed dose limit: $D_{\\mathrm{K,max}} = 20 \\, \\mathrm{Gy}$.\n- Red marrow absorbed dose limit: $D_{\\mathrm{M,max}} = 2.0 \\, \\mathrm{Gy}$.\n- Assumptions: linear kinetics, negligible cross-fire, dose dominated by self-dose.\n\nThe problem is valid. It is based on the standard Medical Internal Radiation Dose (MIRD) formalism used in nuclear medicine dosimetry. The data are consistent, plausible, and sufficient to determine a unique solution. The language is objective and unambiguous.\n\nThe solution proceeds by applying the MIRD formalism. The mean absorbed dose $D(r_k)$ to a target region $r_k$ is given by the sum of contributions from all source regions $r_h$:\n$$D(r_k) = \\sum_{h} \\tilde{A}(r_h) S(r_k \\leftarrow r_h)$$\nwhere $\\tilde{A}(r_h)$ is the time-integrated activity in source region $r_h$, and $S(r_k \\leftarrow r_h)$ is the dose factor, representing the mean absorbed dose in $r_k$ per unit cumulated activity in $r_h$.\n\nThe problem states that cross-fire is negligible and self-dose dominates. This simplifies the equation for each region of interest (tumor $\\mathrm{T}$, kidneys $\\mathrm{K}$, red marrow $\\mathrm{M}$) to consider only the self-dose term. For a generic region $i$, the absorbed dose $D_i$ is:\n$$D_i = \\tilde{A}_i S(i \\leftarrow i)$$\nThe time-integrated activity $\\tilde{A}_i$ is proportional to the total administered activity $A_{\\mathrm{admin}}$. This relationship is given by the pre-therapy measurements:\n$$\\tilde{A}_i = \\left(\\frac{\\tilde{A}_i}{A_{\\mathrm{admin}}}\\right) A_{\\mathrm{admin}}$$\nSubstituting this into the dose equation gives the absorbed dose in region $i$ as a function of the administered activity:\n$$D_i = A_{\\mathrm{admin}} \\left(\\frac{\\tilde{A}_i}{A_{\\mathrm{admin}}}\\right) S(i \\leftarrow i)$$\nThe quantity $(\\tilde{A}_i/A_{\\mathrm{admin}})$ has units of time ($ \\mathrm{h}$), which we denote as $\\tau_i$. So, $\\tau_{\\mathrm{T}} = 0.40 \\, \\mathrm{h}$, $\\tau_{\\mathrm{K}} = 0.18 \\, \\mathrm{h}$, and $\\tau_{\\mathrm{M}} = 0.040 \\, \\mathrm{h}$.\n\nThe primary objective is to deliver a target dose of $D_{\\mathrm{target}} = 24 \\, \\mathrm{Gy}$ to the tumor. We can calculate the required administered activity, which we will call $A_{\\mathrm{admin,T}}$, to achieve this goal:\n$$D_{\\mathrm{target}} = A_{\\mathrm{admin,T}} \\cdot \\tau_{\\mathrm{T}} \\cdot S(\\mathrm{T} \\leftarrow \\mathrm{T})$$\nSolving for $A_{\\mathrm{admin,T}}$:\n$$A_{\\mathrm{admin,T}} = \\frac{D_{\\mathrm{target}}}{\\tau_{\\mathrm{T}} \\cdot S(\\mathrm{T} \\leftarrow \\mathrm{T})}$$\nSubstituting the given values:\n$$A_{\\mathrm{admin,T}} = \\frac{24 \\, \\mathrm{Gy}}{(0.40 \\, \\mathrm{h}) \\cdot (7.5 \\times 10^{-3} \\, \\mathrm{Gy / (MBq \\cdot h)})}$$\n$$A_{\\mathrm{admin,T}} = \\frac{24}{0.003} \\, \\mathrm{MBq} = 8000 \\, \\mathrm{MBq}$$\n\nNext, we must verify that this administered activity does not violate the dose limits for the organs at risk (OARs), the kidneys and red marrow.\nThe absorbed dose to the kidneys, $D_{\\mathrm{K}}$, resulting from an administration of $A_{\\mathrm{admin,T}} = 8000 \\, \\mathrm{MBq}$ is:\n$$D_{\\mathrm{K}} = A_{\\mathrm{admin,T}} \\cdot \\tau_{\\mathrm{K}} \\cdot S(\\mathrm{K} \\leftarrow \\mathrm{K})$$\n$$D_{\\mathrm{K}} = (8000 \\, \\mathrm{MBq}) \\cdot (0.18 \\, \\mathrm{h}) \\cdot (9.0 \\times 10^{-3} \\, \\mathrm{Gy / (MBq \\cdot h)})$$\n$$D_{\\mathrm{K}} = 8000 \\cdot 0.00162 \\, \\mathrm{Gy} = 12.96 \\, \\mathrm{Gy}$$\nThis is below the kidney dose limit: $D_{\\mathrm{K}} = 12.96 \\, \\mathrm{Gy} < D_{\\mathrm{K,max}} = 20 \\, \\mathrm{Gy}$.\n\nThe absorbed dose to the red marrow, $D_{\\mathrm{M}}$, resulting from the same activity is:\n$$D_{\\mathrm{M}} = A_{\\mathrm{admin,T}} \\cdot \\tau_{\\mathrm{M}} \\cdot S(\\mathrm{M} \\leftarrow \\mathrm{M})$$\n$$D_{\\mathrm{M}} = (8000 \\, \\mathrm{MBq}) \\cdot (0.040 \\, \\mathrm{h}) \\cdot (6.0 \\times 10^{-3} \\, \\mathrm{Gy / (MBq \\cdot h)})$$\n$$D_{\\mathrm{M}} = 8000 \\cdot 0.00024 \\, \\mathrm{Gy} = 1.92 \\, \\mathrm{Gy}$$\nThis is below the red marrow dose limit: $D_{\\mathrm{M}} = 1.92 \\, \\mathrm{Gy} < D_{\\mathrm{M,max}} = 2.0 \\, \\mathrm{Gy}$.\n\nSince the administered activity required to achieve the target tumor dose results in OAR doses that are within their respective safety limits, this is the correct activity to administer.\n$$A_{\\mathrm{admin}} = 8000 \\, \\mathrm{MBq}$$\nThe problem requires the answer in gigabecquerels ($\\mathrm{GBq}$). Since $1 \\, \\mathrm{GBq} = 1000 \\, \\mathrm{MBq}$, we convert the result:\n$$A_{\\mathrm{admin}} = 8000 \\, \\mathrm{MBq} \\times \\frac{1 \\, \\mathrm{GBq}}{1000 \\, \\mathrm{MBq}} = 8.00 \\, \\mathrm{GBq}$$\nThe answer is required to be rounded to three significant figures. The value $8.00 \\, \\mathrm{GBq}$ is already expressed to three significant figures.", "answer": "$$\\boxed{8.00}$$", "id": "4936218"}]}